期刊
FUTURE NEUROLOGY
卷 14, 期 3, 页码 -出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fnl-2019-0006
关键词
drug repositioning; motor neuron; neuromuscular disorders; neuromuscular junction; skeletal muscle; spinal muscular atrophy; survival motor neuron; therapies
资金
- Keele University School of Medicine
- Muscular Dystrophy UK
- SMA Angels Charity
- Association Francaise contre les Myopathies
- Action Medical Research
Spinal muscular atrophy (SMA) is a childhood disorder caused by loss of the SMN gene. Pathological hallmarks are spinal cord motor neuron death, neuromuscular junction dysfunction and muscle atrophy. The first SMN genetic therapy was recently approved and other SMN-dependent treatments are not far behind. However, not all SMA patients will reap their maximal benefit due to limited accessibility, high costs and differential effects depending on timing of administration and disease severity. The repurposing of commercially available drugs is an interesting strategy to ensure more rapid and less expensive access to new treatments. In this mini-review, we will discuss the potential and relevance of repositioning drugs currently used for neurodegenerative, neuromuscular and muscle disorders for SMA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据